

UNITED THERAPEUTICS CORP

Form 8-K

May 06, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15 (d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 6, 2003

United Therapeutics Corporation

---

(Exact Name of Registrant as Specified in Charter)

Delaware

000-26301

52-1984749

---

(State or Other  
Jurisdiction of  
Incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification Number)

1110 Spring Street  
Silver Spring, MD

20910

---

(Address of Principal Executive  
Offices)

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

---

**Item 7. Exhibits**

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99	Press release dated May 6, 2003.

**Item 9. Regulation FD Disclosure.**

The information contained in this Item 9 is being furnished to the Securities and Exchange Commission (the Commission) pursuant to Item 12 of Form 8-K, Results of Operations and Financial Condition, as directed by the Commission in Release No. 34-47583.

On May 6, 2003, United Therapeutics Corporation (the Company) issued a press release setting forth its earnings for the Company's quarterly fiscal period ended March 31, 2003. A copy of this press release is attached hereto as Exhibit 99. The Company does not intend for Exhibit 99 to be incorporated by reference into filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: May 6, 2003

By: /s/ Paul A. Mahon  
Name: Paul A. Mahon  
Title: General Counsel

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99	Press release dated May 6, 2003